Top Hybrids and Electric Cars Must Buy 2016 [ Buying Guide ]
Top Recommended Hybrids and Electric Cars
List Car you need to buy:
====== 2016 Tesla Model S ========
We owned a 2013 Tesla Model S for 18 months and despite numerous dealer visits and maintenance issues, we were ultimately sad to see it go. It's quick, comfortable, quiet, spacious, and can tote as much cargo as some crossover SUVs. The "85" version can go 265 miles on a charge, so range anxiety is a nonissue. We even drove ours from L.A. to New York in less than three days using Tesla's free Supercharger quick-charge network. We definitely have gripes, including some underwhelming interior trim pieces and a lack of small item storage. There's also the below-average reliability, although our dealer experiences were exceptional. So even though it's not perfect, the Model S remains our favorite electric car.
============2016 Kia Soul EV============
Kia's first real foray into the electric vehicle world is a success. In fact, the funky Soul is arguably more appealing when it swaps out its internal combustion engine for an electric motor. In our testing, the Soul EV went farther on a charge than its similarly sized and priced competitors, and then recharged quickly thereafter. It also doesn't suffer a reduction in cargo space versus the non-EV Soul, meaning it provides the utility of a small SUV rather than that of a small hatchback like its rivals. A long warranty and generous features are other benefits.
===============2015 BMW i3=============
BMW's i3 is a remarkable vehicle. Its main structure is made of light yet strong carbon fiber instead of the usual steel or aluminum. This helps reduce the i3's weight, which pays dividends for both electric range and performance. With its electric motor in back and the battery under the floor, the i3 boasts sporty acceleration and handling.
======= 2015 BMW i8 ===========
You want your plug-in hybrid to be a head-turning sports car? Look no further than the BMW i8, the two-door supercar for the environmentally conscious. Like the more attainable BMW i3, the i8 is built around a carbon-fiber passenger cell. But in the i8 an electric motor drives the front wheels and a turbocharged three-cylinder gasoline engine pushes from behind.
===== Luxury Hybrid 2016 Porsche Panamera E-Hybrid =====
Porsche's flagship sedan is the Panamera, a low-slung four-door with a hatchback trunk. The 2016 Porsche Panamera S E-Hybrid is the plug-in hybrid version, and it offers 16 miles of pure electric driving before the supercharged 3.0-liter gasoline V6 engine takes over. Acceleration, handling and braking are pure Porsche, which is something of a trick for a car this large. It's perfect for those shoppers
======= Hybrid SUV 2016 Toyota Highlander Hybrid =========
No other automaker bothers to offer a hybrid version of its three-row SUV. But Toyota's Highlander Hybrid doesn't earn a spot in our Buying Guide purely by default. It continues to show just how well the hybrid formula can be applied to a big, family-friendly crossover SUV. The hybrid version earns a 28 mpg combined estimate, or 7-8 mpg better than the V6-powered Highlander. In addition to that, the Highlander Hybrid offers solid build quality, respectable acceleration, a sophisticated and quiet ride quality and plenty of standard and available features.
====== 2016 Toyota Camry Hybrid 2016 Toyota Prius =====
Substantial changes last year vaulted the Toyota Camry Hybrid onto our top-recommended list. Although it doesn't quite match the fuel economy of some competitors, the real-world cost of that difference is negligible. Plus, dismissing the Camry simply because of an mpg or two would mean missing out on an otherwise compelling sedan. Comfort remains a Camry priority, but this latest Camry Hybrid also handles pretty well.
====== Hybrid Cars 2016 Ford Fusion Hybrid / Energi =====
The 2016 Ford Fusion Hybrid is a great choice for car shoppers who are new to hybrids. It's quiet, comfortable and feels very much like a normal family sedan, while delivering the fuel economy you expect from a hybrid. It's also a Ford Fusion, which means you also get impressive refinement, good road manners and plenty of standard and available high-tech features.
======= 2016 Volkswagen e-Golf =====
Among entry-level EVs, the Volkswagen e-Golf is our favorite. It handles well, has a handsome interior, delivers class-competitive range and has the optimal equipment for quick battery recharging. What's even better, cargo space is unchanged from the non-EV Golf because the batteries are located under the floor.
The Pharmaceutical Research and Manufacturers of America (PhRMA) today released new advertising as part of its “From Hope to Cures” campaign, highlighting the stories of rare blood and lung cancer survivors.
The newest video in the collection features Matt, who was diagnosed nearly seven years ago with advanced non-small cell lung cancer. When he was diagnosed, he was given a slim chance of living up to five years. However, today Matt continues to lead an active life due to recent advancements in targeted gene therapies and innovations in cancer medicines.
The latest print and digital ads feature Jamie, a vibrant woman diagnosed 15 years ago with chronic myelogenous leukemia (CML). Watching her son grow up was a primary focus for her, and she’s been able to continue to do that and so much more. Thanks to advancements in CML treatments, today she maintains her sense of humor and imparts an infectious joy on those who meet her.
Earlier this year, the first collection of digital and print ads was released featuring Rhys, a five-year-old living with type 1 diabetes and celiac disease. Unveiled alongside the advertising was a video, titled “We’re Fighting Back,” which features both Rhys and Jamie, as well as Jen, a researcher who wakes up every day working to find new treatments and cures for patients.
To view the multimedia release go to:
http://www.multivu.com/players/English/7738431-phrma-from-hope-to-cures/
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here.
“Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
Combining their expertise in clinical trials support and cellular therapies, BloodCenter of Wisconsin (BCW) and the San Diego Blood Bank (SDBB) have created a strategic partnership to accelerate advancements in research and patient care. Together, BloodCenter of Wisconsin and San Diego Blood Bank will offer Celluvative™ – a portfolio of products and clinical trial services that will include esoteric laboratory testing, blood products for research and manufacturing applications, cell processing, and access to a broad database of diverse donors who have expressed interest in clinical trials.
“Through the strength of our partnership, we are able to offer end-to-end services to academic organizations, research institutions and other industry partners who are working to develop novel cellular therapy approaches,” said Matthew Anderson, M.D., Ph.D., medical director, BloodCenter of Wisconsin Diagnostic Laboratories. “Among other offerings, our Celluvative portfolio enables access to an extremely diverse donor database – an invaluable resource to enable advances in the area of regenerative medicine and drug discovery.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7855451-bloodcenter-sdbb-celluvative/
Soy consumption is up 14 percent since 2011,26 yet confusion lingers over soy’s role in everything from human health to food production. To clear up misperceptions, the United Soybean Board (USB) busts five common soy myths with science-backed facts on SoyConnection.com/soy-wisdom.
1) Eating soy does not increase breast cancer risk.
Clinical studies show soy isoflavone exposure does not adversely affect breast tissue as assessed by markers of breast cancer risk, such as breast cell proliferation.1–7 The American Institute for Cancer Research and the American Cancer Society say that women who have been diagnosed with breast cancer can safely consume soyfoods. In fact, the World Cancer Research Fund International has identified a link between soy consumption and an improved survival of breast cancer patients.8-9
“Not only does evidence indicate soyfoods may benefit women with breast cancer, but consuming soy when young helps prevent the onset of this disease later in life27-30,” stated Mark Messina, Ph.D., who has dedicated the past 30 years to understanding the health effects of soyfoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7877951-united-soybean-board-top-soy-myths/
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
USANA Health Sciences is pleased to announce an innovative technological advancement: its U.S. patent-pending USANA InCelligence Technology™. This exclusive cell-signaling technology—now found in various USANA® products—is designed to help your body’s cells renew and protect themselves in unique and powerful ways, representing a monumental leap forward in cellular nutrition and overall wellness.*
“USANA continues to build a reputation as an innovator in the science of cellular health and nutritional supplementation,” says USANA Founder Dr. Myron Wentz. “With USANA’s InCelligence Technology, we are ensuring that our company remains on the cutting-edge of nutritional supplementation.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7736551-usana-incelligence-technology/
Expanding the functionality of Internet of Things (IoT) networks, Texas Instruments (TI) (NASDAQ: TXN) today announced availability for mass production of the industry’s lowest-power dual-band wireless microcontroller (MCU) supporting Sub-1 GHz and Bluetooth® low energy connectivity on a single chip. As part of TI’s pin-to-pin and software compatible SimpleLink™ ultra-low power platform, the new SimpleLink dual-band CC1350 wireless MCU enables developers to move from a three-chip solution to a tiny single chip, while reducing design complexity, saving power, cost and board space. The CC1350 wireless MCU offers a range of up to 20 km on a coin cell battery for building and factory automation, alarm and security, smart grid, asset tracking and wireless sensor network applications. For more information, visit www.ti.com/cc1350-pr.
To view the multimedia release go to:
http://www.multivu.com/players/English/7746254-texas-instruments-simplelink-dual-band-cc1350/
Match, the world's largest relationship company, today released findings from its seventh annual Singles in America study – the nation’s largest, most comprehensive annual survey of single people living in the U.S. The 2016 survey captures surprising data and trends on new dating rituals, the impact social media has had on the dating landscape, shifting gender roles, as well as attitudes about love, sex, and relationships across generations.
“The annual Singles in America study has once again demonstrated new emerging trends including men’s overwhelmingly positive view of feminism and feminists, in the boardroom and the bedroom. We’ve captured the great spring forward in gender equality,” says Dr. Helen Fisher, biological anthropologist and Chief Scientific Advisor to Match. “Millennials are diligently using technology to find love—and building new dating rules and taboos along the way. Moreover, if you want to spur a budding relationship forward, skip the flowers: leave your cell phone in your pocket. And how do you know when a friendship is turning into a romance? Singles still express true love in ancestral ways -- it’s not about revealing your passwords.”
To view the multimedia release go to:
http://www.multivu.com/players/English/8024551-match-7th-annual-singles-in-america-study/
Today, Genesis unveiled its progressive GV80 Concept SUV at the New York International Auto Show. The new fuel cell concept SUV continues to build on the global brand’s expressive and refined ‘Athletic Elegance’ design direction. The GV80 Concept reveals precision details and a confidently evolved design language that provides subtle glimpses into the bold future of Genesis’ design and product development.
The GV80 Concept is the brand’s first interpretation of a versatile luxury SUV, which strikes a perfect balance between elegance and versatility. On the exterior, this is seen in the concept’s confident posture and athletic prowess, while the spacious interior indulges passengers and immerses them in technology that connects them to the vehicle. Recognizing the brand’s global impact, the GV80 Concept utilizes the latest plug-in hydrogen fuel cell electric technology to combine eco-performance and capability, all skillfully designed to fulfill the needs and explore the escapes of the urban adventurer. Genesis will continue to study the benefits of similar alternative propulsion systems and eco-friendly technologies for future product applications.
To view the multimedia release go to:
https://www.multivu.com/players/English/75060512-hyundai-genesis-gv80-guel-cell-concept-suc-nyais/
We get it, filters are the perfect skin fix for all things social, but what about your real-life beauty routine? Ditch the filters and take the #peelchallenge with Exuviance Performance Peel AP25 to reveal your own radiant, glowing complexion.
Experience the benefits of this high performance 25% blend of Alpha and Poly Hydroxy Acids including Glycolic Acid, Mandelic Acid, and Gluconolactone. Exuviance Performance Peel AP25, developed by the original patent holders of the Glycolic Acid peel, exfoliates dead, dull surface layers, and encourages cell renewal for fresher, healthier-looking skin.
To view the multimedia release go to:
https://www.multivu.com/players/English/7965751-exuviance-performance-peelchallenge-ap25/
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
